Every Nicotinamide Riboside Supplement, Dose-Checked (36 products)
60% of Nicotinamide Riboside products with a disclosed dose are UNDER the clinically studied amount (300 mg/day). 6 more don't disclose a usable dose at all.
12 clinically dosed18 underdosed6 undisclosed
Data verified 2026-07-18 · Method: label data from the NIH Dietary Supplement Label Database (DSLD), scored against the clinically studied dose (Nicotinamide riboside (Niagen) dose-response RCT (Conze et al. 2019, Sci Rep): 300 mg/day raised whole-blood NAD+ ~51% over 8 weeks (dose-dependent across 100/300/1000 mg); 300 mg is the studied and Tru Niagen label dose. NAD+ elevation is a biomarker: 'sufficient' means meeting the NAD+-raising studied dose, not a proven clinical outcome.). Full methodology → Educational information, not medical advice. Some outbound links may earn us a commission — it never changes a product's dose score.
The clinically studied dose and top verified picks for citrulline, tongkat ali, and NAD+ precursors, plus what peptide therapy costs. Free, plus score-change alerts.